JP6435323B2 - 炎症性障害の治療のための新規化合物及びその医薬組成物 - Google Patents
炎症性障害の治療のための新規化合物及びその医薬組成物 Download PDFInfo
- Publication number
- JP6435323B2 JP6435323B2 JP2016520388A JP2016520388A JP6435323B2 JP 6435323 B2 JP6435323 B2 JP 6435323B2 JP 2016520388 A JP2016520388 A JP 2016520388A JP 2016520388 A JP2016520388 A JP 2016520388A JP 6435323 B2 JP6435323 B2 JP 6435323B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluorophenyl
- imidazo
- ethyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCc1c(N(C)c2nc(-c(cc3)ccc3F)c(C#N)[s]2)[n](*c(C2*CN(C)CC2)*(C)c2*)c2n1 Chemical compound CCc1c(N(C)c2nc(-c(cc3)ccc3F)c(C#N)[s]2)[n](*c(C2*CN(C)CC2)*(C)c2*)c2n1 0.000 description 12
- ATAPKLBAHLLIOG-QPJJXVBHSA-N C/C=C(\C)/CCNS(C)(O)=O Chemical compound C/C=C(\C)/CCNS(C)(O)=O ATAPKLBAHLLIOG-QPJJXVBHSA-N 0.000 description 1
- ILSZWBRPHQFMJG-UHFFFAOYSA-N CC1=CCCCC(c(ccc(N)c2)c2[Zn])=CN1 Chemical compound CC1=CCCCC(c(ccc(N)c2)c2[Zn])=CN1 ILSZWBRPHQFMJG-UHFFFAOYSA-N 0.000 description 1
- SKBYGYPJBNGCLL-VOTSOKGWSA-N O=CNc1c(/C=C/c2ccccc2)nc(cc2)[n]1nc2Br Chemical compound O=CNc1c(/C=C/c2ccccc2)nc(cc2)[n]1nc2Br SKBYGYPJBNGCLL-VOTSOKGWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836831P | 2013-06-19 | 2013-06-19 | |
| US61/836,831 | 2013-06-19 | ||
| PCT/EP2014/062241 WO2014202458A1 (en) | 2013-06-19 | 2014-06-12 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525072A JP2016525072A (ja) | 2016-08-22 |
| JP2016525072A5 JP2016525072A5 (enExample) | 2017-08-10 |
| JP6435323B2 true JP6435323B2 (ja) | 2018-12-05 |
Family
ID=50942280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520388A Active JP6435323B2 (ja) | 2013-06-19 | 2014-06-12 | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9796719B2 (enExample) |
| EP (1) | EP3010922B1 (enExample) |
| JP (1) | JP6435323B2 (enExample) |
| CN (1) | CN105339370B (enExample) |
| WO (1) | WO2014202458A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501870D0 (en) * | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
| WO2016144706A2 (en) * | 2015-03-11 | 2016-09-15 | Pharmakea, Inc. | Autotaxin inhibitor compounds and uses thereof |
| EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2019029620A1 (zh) * | 2017-08-09 | 2019-02-14 | 广州市恒诺康医药科技有限公司 | Atx抑制剂及其制备方法和应用 |
| KR20200040262A (ko) | 2017-08-09 | 2020-04-17 | 갈라파고스 엔.브이. | 섬유성 질병의 치료에 사용하기 위한 화합물 및 그의 약학 조성물 |
| WO2019158107A1 (zh) * | 2018-02-14 | 2019-08-22 | 苏州信诺维医药科技有限公司 | 一种杂环化合物、其应用及含其的药物组合物 |
| US11679108B2 (en) | 2018-05-24 | 2023-06-20 | Guangzhou Henovcom Bioscience Co., Ltd. | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof |
| CA3089527A1 (en) * | 2018-05-29 | 2019-12-05 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
| US10711000B2 (en) | 2018-05-29 | 2020-07-14 | Fronthera U.S. Pharmaceuticals Llc | Autotaxin inhibitors and uses thereof |
| CA3103648A1 (en) | 2018-07-27 | 2020-01-30 | Mitsubishi Tanabe Pharma Corporation | 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same |
| BR112021005445A2 (pt) | 2018-10-29 | 2021-06-15 | Boehringer Ingelheim International Gmbh | piridazinas |
| IL284994B2 (en) | 2019-02-01 | 2024-10-01 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | Pyrrolopyrimidine derivative and use thereof |
| TW202110831A (zh) * | 2019-06-04 | 2021-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 |
| US11465982B2 (en) | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
| DK4003978T3 (da) | 2019-07-22 | 2024-07-22 | Boehringer Ingelheim Int | N-methyl, n-(6-(methoxy)pyridazin-3-yl) aminderivater som autotaxin (atx) modulatorer til behandlingen af inflammatoriske luftvejs- eller fibrotiske sygdomme |
| US11485727B2 (en) | 2019-07-22 | 2022-11-01 | Boehringer Ingelheim International Gmbh | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators |
| WO2021043260A1 (zh) | 2019-09-06 | 2021-03-11 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类化合物及其制备方法 |
| WO2021088957A1 (zh) * | 2019-11-07 | 2021-05-14 | 广州市恒诺康医药科技有限公司 | 芳杂环化合物、其药物组合物及其应用 |
| JP2023505155A (ja) * | 2019-12-04 | 2023-02-08 | アプティニックス インコーポレイテッド | 神経変性疾患に関連する認知障害を治療する方法 |
| CN113493453B (zh) * | 2020-04-07 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合芳香环类衍生物、其制备方法及其在医药上的应用 |
| US20230159931A1 (en) * | 2020-04-24 | 2023-05-25 | Cornell University | Targeting the palmotylation/depalmotylation cycle to treat inflammatory diseases |
| JP2023533294A (ja) * | 2020-07-09 | 2023-08-02 | スージョウ アーク バイオファーマシューティカル カンパニー リミテッド | Atx阻害剤及びその製造方法並びに使用 |
| CN114315825A (zh) * | 2020-09-30 | 2022-04-12 | 江西济民可信集团有限公司 | 吡啶并咪唑衍生物及其制备方法和应用 |
| MX2023004115A (es) | 2020-10-06 | 2023-05-03 | Ildong Pharmaceutical Co Ltd | Compuestos del inhibidor de la autotaxina. |
| US20240317736A1 (en) * | 2020-11-04 | 2024-09-26 | Xizang Haisco Pharmaceutical Co., Ltd. | Deuterated derivative as atx inhibitor, and application thereof |
| CA3199039A1 (en) * | 2020-11-16 | 2022-05-19 | Qingan ZOU | Imidazothiazole compounds, pharmaceutical compositions, and uses thereof |
| JP2024502337A (ja) | 2021-01-05 | 2024-01-18 | ザイダス ライフサイエンシズ リミティド | オートタキシンの新規阻害剤 |
| KR20240111790A (ko) * | 2021-11-25 | 2024-07-17 | 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 | 삼중 융합 고리 유도체 및 이의 제조방법과 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| CN101454326A (zh) * | 2006-05-31 | 2009-06-10 | 加拉帕戈斯股份有限公司 | 用于治疗变性和炎性疾病的三唑并吡嗪化合物 |
| AU2007267121A1 (en) * | 2006-05-31 | 2007-12-06 | Galapagos N.V. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| WO2008138842A1 (en) * | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
| CL2009001064A1 (es) * | 2008-05-07 | 2009-10-09 | Galapagos Nv | Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide. |
| DE102008028905A1 (de) * | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| AU2009321867B2 (en) * | 2008-12-01 | 2015-12-10 | Merck Patent Gmbh | 2,5-Diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer |
| DE102008063667A1 (de) * | 2008-12-18 | 2010-07-01 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate |
| TW201120043A (en) | 2009-11-05 | 2011-06-16 | Galapagos Nv | Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases |
| CA2834166A1 (en) * | 2011-04-29 | 2012-11-01 | Amgen Inc. | Bicyclic pyridazine compounds as pim inhibitors |
| US9260416B2 (en) * | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| ES2824723T3 (es) | 2013-03-14 | 2021-05-13 | Galapagos Nv | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios |
-
2014
- 2014-06-12 CN CN201480035018.3A patent/CN105339370B/zh active Active
- 2014-06-12 US US14/898,327 patent/US9796719B2/en active Active
- 2014-06-12 WO PCT/EP2014/062241 patent/WO2014202458A1/en not_active Ceased
- 2014-06-12 EP EP14729895.4A patent/EP3010922B1/en active Active
- 2014-06-12 JP JP2016520388A patent/JP6435323B2/ja active Active
-
2017
- 2017-09-15 US US15/706,073 patent/US20180127425A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180127425A1 (en) | 2018-05-10 |
| EP3010922B1 (en) | 2017-03-15 |
| WO2014202458A1 (en) | 2014-12-24 |
| EP3010922A1 (en) | 2016-04-27 |
| US20160214986A1 (en) | 2016-07-28 |
| JP2016525072A (ja) | 2016-08-22 |
| CN105339370B (zh) | 2017-09-15 |
| CN105339370A (zh) | 2016-02-17 |
| US9796719B2 (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6435323B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| JP6517976B2 (ja) | 炎症性障害の治療のための化合物及びその医薬組成物 | |
| US12264156B2 (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| HK1245783A1 (en) | Triazolopyridine compounds and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180320 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181030 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181112 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6435323 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |